MCID: LSC001
MIFTS: 61

Lesch-Nyhan Syndrome malady

Categories: Genetic diseases, Rare diseases, Metabolic diseases, Neuronal diseases, Nephrological diseases, Blood diseases, Mental diseases

Aliases & Classifications for Lesch-Nyhan Syndrome

About this section
Sources:
49OMIM, 10Disease Ontology, 11diseasecard, 68Wikipedia, 21GeneReviews, 45NIH Rare Diseases, 22GeneTests, 23Genetics Home Reference, 46NINDS, 47Novoseek, 12DISEASES, 51Orphanet, 67UniProtKB/Swiss-Prot, 36MeSH, 65UMLS, 24GTR, 27ICD10, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Lesch-Nyhan Syndrome:

Name: Lesch-Nyhan Syndrome 49 10 11 68 21 45 22 23 46 47 12 51 67 36 65
Complete Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency 10 68 23
Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency 10 21 22
Hypoxanthine Guanine Phosphoribosyltransferase Deficiency 10 45 23
Lesch-Nyhan Disease 21 22 23
Hgprt Deficiency 21 22 23
Hprt Deficiency 21 45 22
Lns 45 23 67
Total Hypoxanthine-Guanine Phosphoribosyl Transferase Deficiency 68 23
Juvenile Gout, Choreoathetosis, Mental Retardation Syndrome 68 23
X-Linked Uric Aciduria Enzyme Defect 68 23
Juvenile Hyperuricemia Syndrome 68 23
X-Linked Primary Hyperuricemia 68 23
Primary Hyperuricemia Syndrome 68 23
Complete Hprt Deficiency 68 23
X-Linked Hyperuricemia 10 23
Total Hprt Deficiency 68 23
Lesch Nyhan Disease 45 24
Hypoxanthine Guanine Phosphoribosyltransferase Deficiency, Grade Iv 51
 
Hypoxanthine Guanine Phosphoribosyltransferase Complete Deficiency 51
Hprt - Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency 68
Hypoxanthine Guanine Phospho-Ribosyltransferase 1 Deficiency 45
Hypoxanthine-Guanine-Phosphoribosyltransferase Deficiency 10
Choreoathetosis Self-Mutilation Hyperuricemia Syndrome 68
Deficiency of Hypoxanthine Phosphoribosyltransferase 23
Hypoxanthine Phosphoribosyltransferse Deficiency 68
Hypoxanthine Phosphoribosyltransferase Deficiency 23
Deficiency of Guanine Phosphoribosyltransferase 23
Choreoathetosis Self-Mutilation Syndrome 23
Deficiency of Imp Pyrophosphorylase 10
Hprt Deficiency, Complete 45
Hprt Complete Deficiency 51
Hprt Deficiency Grade Iv 51
Lesch - Nyhan Syndrome 10
Lesch Nyhan Syndrome 45
Hg-Prt Deficiency 10
Hprt1 Deficiency 45
Lnd 23

Characteristics:

Orphanet epidemiological data:

51
lesch-nyhan syndrome:
Inheritance: X-linked recessive; Prevalence: 1-9/1000000 (Europe); Age of onset: Infancy

HPO:

61
lesch-nyhan syndrome:
Inheritance: x-linked recessive inheritance


Classifications:



External Ids:

OMIM49 300322
Disease Ontology10 DOID:1919
ICD1027 E79.1, E79.0
MeSH36 D007926
NCIt42 C61255
Orphanet51 510
ICD10 via Orphanet28 E79.1
MESH via Orphanet37 D007926
UMLS via Orphanet66 C0023374
UMLS65 C0023374

Summaries for Lesch-Nyhan Syndrome

About this section
NIH Rare Diseases:45 Lesch nyhan syndrome is a condition characterized by neurological and behavioral abnormalities and the overproduction of uric acid in the body. it occurs almost exclusively in males. signs and symptoms may include inflammatory arthritis (gout), kidney stones, bladder stones, and moderate cognitive disability. nervous system and behavioral disturbances also occur, such as involuntary muscle movements and self injury (including biting and head banging). people with lesch nyhan syndrome usually cannot walk, require assistance sitting, and generally use a wheelchair. lesch nyhan syndrome is caused by changes (mutations) in the hprt1 gene and is inherited in an x-linked recessive manner. treatment is symptomatic and supportive. affected people often do not survive past the first or second decade of life due to renal failure. last updated: 1/13/2015

MalaCards based summary: Lesch-Nyhan Syndrome, also known as complete hypoxanthine-guanine phosphoribosyltransferase deficiency, is related to hprt-related gout and hypoxanthine guanine phosphoribosyltransferase partial deficiency, and has symptoms including behavioral abnormality, hypertonia and arthritis. An important gene associated with Lesch-Nyhan Syndrome is HPRT1 (Hypoxanthine Phosphoribosyltransferase 1), and among its related pathways are Nucleotide Metabolism and purine nucleotides de novo biosynthesis. Affiliated tissues include kidney, skin and breast, and related mouse phenotypes are endocrine/exocrine gland and integument.

Genetics Home Reference:23 Lesch-Nyhan syndrome is a condition that occurs almost exclusively in males. It is characterized by neurological and behavioral abnormalities and the overproduction of uric acid. Uric acid is a waste product of normal chemical processes and is found in blood and urine. Excess uric acid can be released from the blood and build up under the skin and cause gouty arthritis (arthritis caused by an accumulation of uric acid in the joints). Uric acid accumulation can also cause kidney and bladder stones.

NINDS:46 Lesch-Nyhan syndrome (LNS) is a rare, inherited disorder caused by a deficiency of the enzyme (HPRT. LNS is an X-linked recessive disease-- the gene is carried by the mother and passed on to her son.

UniProtKB/Swiss-Prot:67 Lesch-Nyhan syndrome: Characterized by complete lack of enzymatic activity that results in hyperuricemia, choreoathetosis, mental retardation, and compulsive self-mutilation.

Wikipedia:68 Lesch–Nyhan syndrome (LNS), also known as Nyhan\'s syndrome and juvenile gout, is a rare inherited... more...

Description from OMIM:49 300322

GeneReviews summary for NBK1149

Related Diseases for Lesch-Nyhan Syndrome

About this section

Graphical network of the top 20 diseases related to Lesch-Nyhan Syndrome:



Diseases related to lesch-nyhan syndrome

Symptoms for Lesch-Nyhan Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

300322

Clinical features from OMIM:

300322

Symptoms:

 51 (show all 11)
  • movement disorder
  • hypertonia/spasticity/rigidity/stiffness
  • hemiplegia/diplegia/hemiparesia/limb palsy
  • intellectual deficit/mental/psychomotor retardation/learning disability
  • psychic/behavioural troubles
  • arthritis/synovitis/synovial proliferation
  • hyperuricemia
  • x-linked recessive inheritance
  • renal failure
  • hematuria/microhematuria
  • anaemia

HPO human phenotypes related to Lesch-Nyhan Syndrome:

(show all 28)
id Description Frequency HPO Source Accession
1 behavioral abnormality hallmark (90%) HP:0000708
2 hypertonia hallmark (90%) HP:0001276
3 arthritis hallmark (90%) HP:0001369
4 hyperuricemia hallmark (90%) HP:0002149
5 hemiplegia/hemiparesis hallmark (90%) HP:0004374
6 abnormality of movement hallmark (90%) HP:0100022
7 cognitive impairment hallmark (90%) HP:0100543
8 renal insufficiency typical (50%) HP:0000083
9 hematuria typical (50%) HP:0000790
10 anemia typical (50%) HP:0001903
11 short stature HP:0004322
12 hyperuricosuria HP:0003149
13 opisthotonus HP:0002179
14 abnormality of extrapyramidal motor function HP:0002071
15 dysphagia HP:0002015
16 vomiting HP:0002013
17 megaloblastic anemia HP:0001889
18 gout (feet) HP:0001854
19 hyperreflexia HP:0001347
20 dystonia HP:0001332
21 motor delay HP:0001270
22 choreoathetosis HP:0001266
23 dysarthria HP:0001260
24 spasticity HP:0001257
25 muscular hypotonia HP:0001252
26 intellectual disability HP:0001249
27 nephrolithiasis HP:0000787
28 testicular atrophy HP:0000029

Drugs & Therapeutics for Lesch-Nyhan Syndrome

About this section

Drugs for Lesch-Nyhan Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 3, Phase 1308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2Neurotransmitter AgentsPhase 3, Phase 114795
3Psychotropic DrugsPhase 3, Phase 15501
4ecopipamPhase 3, Phase 16
5Tranquilizing AgentsPhase 3, Phase 13597
6Dopamine AntagonistsPhase 3, Phase 1927
7Central Nervous System DepressantsPhase 3, Phase 110016
8Dopamine AgentsPhase 3, Phase 13084
9Antipsychotic AgentsPhase 3, Phase 12130

Interventional clinical trials:

idNameStatusNCT IDPhase
1Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan DiseaseTerminatedNCT01751802Phase 3
2Trial of Kuvan in Lesch-Nyhan DiseaseWithdrawnNCT00935753Phase 2, Phase 3
3Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan DiseaseCompletedNCT00004314Phase 2
4Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan DiseaseCompletedNCT01065558Phase 1

Search NIH Clinical Center for Lesch-Nyhan Syndrome


Cochrane evidence based reviews: lesch-nyhan syndrome

Genetic Tests for Lesch-Nyhan Syndrome

About this section

Genetic tests related to Lesch-Nyhan Syndrome:

id Genetic test Affiliating Genes
1 Lesch-Nyhan Syndrome22 HPRT1

Anatomical Context for Lesch-Nyhan Syndrome

About this section

MalaCards organs/tissues related to Lesch-Nyhan Syndrome:

33
Kidney, Skin, Breast, T cells, Heart, Bone, Brain

Animal Models for Lesch-Nyhan Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Lesch-Nyhan Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053798.4FGA, HPRT1, RAPGEF4, SLC6A3, XDH
2MP:00107717.8APRT, FGA, HPRT1, NGF, SLC6A3, XDH
3MP:00053697.5HPRT1, NGF, RAPGEF4, SLC6A3, XDH
4MP:00107687.1ADSL, APRT, FGA, HPRT1, NGF, SLC6A3
5MP:00053766.8APRT, FGA, HPRT1, NGF, RAPGEF4, SLC6A3

Publications for Lesch-Nyhan Syndrome

About this section

Articles related to Lesch-Nyhan Syndrome:

(show top 50)    (show all 370)
idTitleAuthorsYear
1
Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice. (26297559)
2015
2
Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses. (26537743)
2015
3
Microparticle source and tissue factor expression in pregnancy. (25823853)
2015
4
Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response. (24559095)
2014
5
A rare case of multifocal intramedullary germinoma in cervical spinal cord. (24902643)
2014
6
Regulation of neutrophil apoptosis differs after in vivo transmigration to skin chambers and synovial fluid: a role for inflammasome-dependent interleukin-1I^ release. (23571448)
2013
7
Correlation of P53 and granzyme B expression in oral squamous cell carcinoma with clinicopathologic findings. (23981150)
2013
8
A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. (23446068)
2013
9
Distinguishable in vitro binding mode of monomeric TRBP and dimeric PACT with siRNA. (23658827)
2013
10
Tolerant anti-insulin B cells are effective APCs. (23396943)
2013
11
Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell. (24294361)
2013
12
Characterization of a new human melanoma cell line with CD133 expression. (22529031)
2012
13
Imaging EGFR phosphorylation in intact human pancreatic carcinoma cells. (22773576)
2012
14
Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. (21742369)
2011
15
Chromophobe renal cell carcinoma with neuroendocrine differentiation and sarcomatoid change. (21884307)
2011
16
Panniculitis ossificans non-traumatica of the scalp. (19615016)
2010
17
Hysterotomy and evacuation of a deciduate placental hematoma following placental abruption. (20624620)
2010
18
Non-paraneoplastic limbic encephalitis associated with NMDAR and VGKC antibodies. (20667865)
2010
19
Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. (19720934)
2009
20
Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes in a Brazilian population. (19330589)
2009
21
Prognosis and treatment of spinal cord astrocytoma. (18687533)
2009
22
The management of exfoliative glaucoma. (18929111)
2008
23
Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. (18224662)
2008
24
Gabapentin can improve postural stability and quality of life in primary orthostatic tremor. (15719416)
2005
25
Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation. (15625104)
2005
26
BLyS--an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. (15288003)
2004
27
Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins. (15006371)
2004
28
Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. (12727890)
2003
29
Patterns of chemokines and chemokine receptors expression in different forms of human periodontal disease. (12608917)
2003
30
Initiating oncogenic event determines gene-expression patterns of human breast cancer models. (12011455)
2002
31
Cerebrospinal fluid leak after acoustic neuroma surgery: influence of tumor size and surgical approach on incidence and response to treatment. (11213957)
2001
32
The occ1 gene is preferentially expressed in the primary visual cortex in an activity-dependent manner: a pattern of gene expression related to the cytoarchitectonic area in adult macaque neocortex. (11168534)
2001
33
Oral contraceptives and central retinal vein occlusion. (11837489)
2001
34
Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. (11040195)
2000
35
Florid reactive periostitis ossificans of the proximal aspect of the tibia: a lesion that must be distinguished from osteosarcoma. A case report. (10428133)
1999
36
Protein phosphorylation signaling mechanisms in carotid body chemoreception. (10592379)
1999
37
Proteolipid protein gene product can be secreted and exhibit biological activity during early development. (10066267)
1999
38
Effects of dietary supplementation with n-3 fatty acid ethyl esters on coccidiosis in chickens. (9835336)
1998
39
Swelling-activated chloride currents in a drug-sensitive cell line and a P glycoprotein-expressing derivative are underlied by channels with the same pharmacological properties. (9792953)
1998
40
Pathogenesis of infantile hypertrophic pyloric stenosis: recent progress. (9553181)
1998
41
Venlafaxine in dysthymic disorder. (9448655)
1997
42
Adrenocorticotropin receptor and adrenal disorders. (9167964)
1997
43
Metabolism of hydroperoxy-phospholipids in human hepatoma HepG2 cells. (8978487)
1996
44
Rescue of Sendai virus cDNA templates with cDNA clones expressing parainfluenza virus type 3 N, P and L proteins. (8887479)
1996
45
Two-stage nucleotide binding mechanism and its implications to H+ transport inhibition of the uncoupling protein from brown adipose tissue mitochondria. (8672485)
1996
46
Familial inclusion body myositis among Kurdish-Iranian Jews. (1850594)
1991
47
Effects of vitamin D-binding protein on bone resorption stimulated by 1,25 dihydroxyvitamin D3. (2224592)
1990
48
Benign concentric annular macular dystrophy. (4412179)
1974
49
Pelvic lipomatosis: a rare cause of suprapubic mass. (4695094)
1973
50

Variations for Lesch-Nyhan Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Lesch-Nyhan Syndrome:

67 (show all 35)
id Symbol AA change Variation ID SNP ID
1HPRT1p.Val8GlyVAR_006751
2HPRT1p.Gly16AspVAR_006752
3HPRT1p.Leu41ProVAR_006756
4HPRT1p.Ile42PheVAR_006757
5HPRT1p.Ile42ThrVAR_006758
6HPRT1p.Arg45LysVAR_006760
7HPRT1p.Ala50ValVAR_006762
8HPRT1p.Ala50ProVAR_006763
9HPRT1p.Arg51ProVAR_006765
10HPRT1p.Met54LeuVAR_006769
11HPRT1p.Met57ThrVAR_006770
12HPRT1p.Gly70GluVAR_006773
13HPRT1p.Gly71ArgVAR_006774
14HPRT1p.Phe74LeuVAR_006775
15HPRT1p.Val130AspVAR_006780
16HPRT1p.Leu131SerVAR_006781
17HPRT1p.Ile132ThrVAR_006783
18HPRT1p.Met143LysVAR_006785
19HPRT1p.Ser162ArgVAR_006788
20HPRT1p.Pro176LeuVAR_006790
21HPRT1p.Asp177ValVAR_006791
22HPRT1p.Asp177TyrVAR_006792
23HPRT1p.Asp194AsnVAR_006798
24HPRT1p.Phe199ValVAR_006800
25HPRT1p.Asp201TyrVAR_006803
26HPRT1p.His204AspVAR_006804
27HPRT1p.His204ArgVAR_006805
28HPRT1p.Cys206TyrVAR_006806
29HPRT1p.Asp44TyrVAR_071611
30HPRT1p.Ala64ProVAR_071613
31HPRT1p.Leu65ProVAR_071614
32HPRT1p.Tyr72CysVAR_071615
33HPRT1p.Leu78GlnVAR_071616
34HPRT1p.Leu147ProVAR_071619
35HPRT1p.Lys159GluVAR_071620

Clinvar genetic disease variations for Lesch-Nyhan Syndrome:

5 (show all 40)
id Gene Variation Type Significance SNP ID Assembly Location
1HPRT1HPRT CHICAGOinsertionPathogenic
2HPRT1HPRT CONNERSVILLEdeletionPathogenic
3HPRT1NM_000194.2(HPRT1): c.122T> C (p.Leu41Pro)single nucleotide variantPathogenicrs137852480GRCh37Chr X, 133607483: 133607483
4HPRT1NM_000194.2(HPRT1): c.643_*6del21 (p.Lys215fs)deletionPathogenicrs387906428GRCh37Chr X, 133634093: 133634113
5HPRT1NM_000194.2(HPRT1): c.222C> A (p.Phe74Leu)single nucleotide variantPathogenicrs137852481GRCh37Chr X, 133609298: 133609298
6HPRT1NM_000194.2(HPRT1): c.580G> A (p.Asp194Asn)single nucleotide variantPathogenicrs267606863GRCh37Chr X, 133632685: 133632685
7HPRT1HPRT MICHIGANdeletionPathogenic
8HPRT1NM_000194.2(HPRT1): c.389T> A (p.Val130Asp)single nucleotide variantPathogenicrs137852483GRCh37Chr X, 133624222: 133624222
9HPRT1NM_000194.2(HPRT1): c.595T> G (p.Phe199Val)single nucleotide variantPathogenicrs137852486GRCh37Chr X, 133632700: 133632700
10HPRT1NM_000194.2(HPRT1): c.209G> A (p.Gly70Glu)single nucleotide variantPathogenicrs137852487GRCh37Chr X, 133609285: 133609285
11HPRT1NM_000194.2(HPRT1): c.325C> T (p.Gln109Ter)single nucleotide variantPathogenicrs137852489GRCh37Chr X, 133620501: 133620501
12HPRT1NM_000194.2(HPRT1): c.610C> G (p.His204Asp)single nucleotide variantPathogenicrs137852490GRCh37Chr X, 133634060: 133634060
13HPRT1NM_000194.2(HPRT1): c.134G> A (p.Arg45Lys)single nucleotide variantPathogenicrs137852491GRCh37Chr X, 133607495: 133607495
14HPRT1NM_000194.2(HPRT1): c.529G> T (p.Asp177Tyr)single nucleotide variantPathogenicrs137852492GRCh37Chr X, 133632463: 133632463
15HPRT1HPRT, 2-BP DEL, GTdeletionPathogenic
16HPRT1HPRT, 1-BP DEL, TTA-TAdeletionPathogenic
17HPRT1HPRT, 1-BP DEL, TTG-TGdeletionPathogenic
18HPRT1HPRT, 40-BP DELdeletionPathogenic
19HPRT1HPRT, IVS8DS, G-A, +5single nucleotide variantPathogenic
20HPRT1NM_000194.2(HPRT1): c.610-4_610-2delATAinsTTTindelPathogenicrs672601245GRCh37Chr X, 133634056: 133634058
21HPRT1HPRT, IVS7DS, G-A, +5single nucleotide variantPathogenic
22HPRT1HPRT, IVS1AS, A-T, -2single nucleotide variantPathogenic
23HPRT1NM_000194.2(HPRT1): c.527C> T (p.Pro176Leu)single nucleotide variantPathogenicrs137852493GRCh37Chr X, 133632461: 133632461
24HPRT1NM_000194.2(HPRT1): c.151C> T (p.Arg51Ter)single nucleotide variantPathogenicrs137852494GRCh37Chr X, 133609227: 133609227
25HPRT1NM_000194.2(HPRT1): c.428T> A (p.Met143Lys)single nucleotide variantPathogenicrs137852496GRCh37Chr X, 133627563: 133627563
26HPRT1NM_000194.2(HPRT1): c.508C> T (p.Arg170Ter)single nucleotide variantPathogenicrs137852497GRCh37Chr X, 133632442: 133632442
27HPRT1HPRT, EX2DELdeletionPathogenic
28HPRT1HPRT, EX4-9DELdeletionPathogenic
29HPRT1NG_012329.1: g.(38034_38038)_(46028_46032)deldeletionPathogenicGRCh38Chr X, 134493178: 134501176
30HPRT1HPRT, EX9DELdeletionPathogenic
31HPRT1HPRT, DELdeletionPathogenic
32HPRT1HPRT,1-BP INS, 207GinsertionPathogenic
33HPRT1HPRT, INV/DEL, EX6-9deletionPathogenic
34HPRT1HPRT, EX2-3DUP, IVS1DELduplicationPathogenic
35HPRT1HPRT CHERMSIDEdeletionPathogenic
36HPRT1HPRT COORPAROOinsertionPathogenic
37HPRT1NM_000194.2(HPRT1): c.419G> A (p.Gly140Asp)single nucleotide variantPathogenicrs137852503GRCh37Chr X, 133627554: 133627554
38HPRT1NM_000194.2(HPRT1): c.459T> G (p.Tyr153Ter)single nucleotide variantPathogenicrs137852505GRCh37Chr X, 133627594: 133627594
39HPRT1NM_000194.2(HPRT1): c.-707_27+2236deldeletionPathogenicGRCh38Chr X, 134459605: 134462608
40HPRT1NM_000194.2(HPRT1): c.212dupG (p.Tyr72Leufs)duplicationPathogenicrs786200980GRCh37Chr X, 133609288: 133609288

Expression for genes affiliated with Lesch-Nyhan Syndrome

About this section
Search GEO for disease gene expression data for Lesch-Nyhan Syndrome.

Pathways for genes affiliated with Lesch-Nyhan Syndrome

About this section

Pathways related to Lesch-Nyhan Syndrome according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.7ADSL, HPRT1
2
Show member pathways
9.4APRT, HPRT1, PNP
3
Show member pathways
9.3FGA, RAPGEF4
4
Show member pathways
8.6FGA, RAPGEF4
5
Show member pathways
8.6ADSL, APRT, HPRT1, PNP, XDH

GO Terms for genes affiliated with Lesch-Nyhan Syndrome

About this section

Biological processes related to Lesch-Nyhan Syndrome according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1adenine metabolic processGO:004608310.4APRT, HPRT1
2purine nucleotide biosynthetic processGO:000616410.3ADSL, HPRT1
3lactationGO:00075959.9SLC6A3, XDH
4nucleobase-containing small molecule metabolic processGO:00550869.8APRT, HPRT1, XDH
5locomotory behaviorGO:00076269.6HPRT1, SLC6A3
6purine nucleobase metabolic processGO:00061448.9ADSL, APRT, HPRT1, PNP, XDH
7small molecule metabolic processGO:00442818.5APRT, HPRT1, RAPGEF4, XDH

Sources for Lesch-Nyhan Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet